ACSL1 and nonpapillary renal cell carcinoma: Meanwhile, low expression of ACSL1 in ccRCC might be suitable for PI3K pathway inhibitors, while high expression of ACSL1 might have better clinical outcomes by using TKI-targeted drugs.